Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Ritonavir-Boosted Elvitegravir in HIV-1
NCT00445146Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Feb 2007
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of elvitegravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Started Feb 2007; status: completed.
02
Drugs
elvitegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00445146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00445146.